Simcha Therapeutics

📍 New Haven, United States👥 14 employees💰 Last funded 2020
Biotechnology Research🌐 simchatx.com
Website LinkedIn
Simcha Therapeutics is a clinical-stage immunobiology company pioneering the development of first-in-class engineered cytokine therapeutics with transformational promise for patients. The company is built on a foundation of scientific rigor to overcome biological challenges in clinically translatable pathways, exemplified by the first decoy-resistant interleukin-18 (IL-18). By unlocking the potential of IL-18, Simcha is developing its lead program (ST-067) as monotherapy and in combination with potentially several other anticancer agents. ST-067 is currently being studied in a Phase 1/2 clinical trial, in patients with solid tumors and who have progressed on other immunotherapeutic agents. Beyond IL-18, the company’s underlying approach to immune-biology and cytokine engineering has broader potential to support disease-modifying therapeutic options for a range of significant diseases.
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Simcha Therapeutics?
Simcha Therapeutics has 2 investors on record on gritt.io.
When did Simcha Therapeutics last raise funding?
The most recent investment in Simcha Therapeutics recorded on gritt.io was in 2020.
What industry is Simcha Therapeutics in?
Simcha Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Simcha Therapeutics based?
Simcha Therapeutics is headquartered in New Haven, United States.